If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

The European Medicines Agency (EMA) said Votrient (pazopanib) can affect melanin production in patients. The EMA reports that among the most common side effects of Votrient, occurring in more than 1 ...

McKinsey report says Indian pharma rose to global prominence led by export boom & improved compliance: Shardul Nautiyal, Mumbai Saturday, March 1, 2025, 08:00 Hrs [IST] McKinsey & ...

In a study published today in Biofunctional Materials, Prof. Dr. Haidar, Founder and CEO of BioMAT'X I+D+I LABs in Santiago, Chile, unveils a ...

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including a Phase 3 trial for pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug ...

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, ...

Copyright © 2025 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.

Copyright © 2025 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.